ArticleBMC infectious diseases2025
Lassa fever survivors: long-term health effects and chronic sequelae - a scoping review.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Temporal dynamics, climate associations, and surveillance performance of Lassa fever in Nigeria, 2020-2025: a national longitudinal analysis.Osong public health and research perspectives · 2026Article
- Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- The persistence and mortality of Lassa fever in Nigeria reflect systemic clinical and diagnostic challenges rather than viral reemergence alone.Frontiers in epidemiology · 2026Article
- Missed Opportunities for Timely Diagnosis and Effective Therapeutic Management of Prolonged Fever: A Case Study of Confirmed Lassa Fever in N'Zérékoré, Guinea, 2022.Case reports in infectious diseases · 2026Article
- A promising therapeutic approach for post-Lassa fever sensorineural hearing loss: a case report.Oxford medical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLassa fever is a viral haemorrhagic disease endemic to West Africa. While most infections are mild, severe cases have high morbidity and mortality, with case fatality rates ranging from 15% in mild cases to 60% in severe cases. Survivors often experience chronic health complications, but these long-term effects remain understudied despite their public health significance.
objectivesThis scoping review synthesises evidence on the long-term health sequelae of Lassa fever, maps key findings from existing studies, and identifies critical gaps to guide future research and clinical care.
methodsA systematic literature search was conducted in PubMed/MEDLINE, Embase, and Google Scholar (up to September 2024) for English-language studies reporting physical, psychological, and functional outcomes ≥ 4 weeks post-recovery. Studies were selected using PCC framework (Population: Lassa survivors; Concept: Long-term sequelae; Context: Endemic regions globally). PRISMA-ScR guidelines were followed.
resultsNine (9) studies from Nigeria, Sierra Leone and Germany were included, comprising three cross-sectional studies, two case-control studies, two case reports, one retrospective descriptive study and one retrospective cohort study. Hearing loss was the most prevalent sequela (16–35% of survivors), often bilateral and sensorineural with associated balance disorders (55%) and social isolation. Neurological sequelae included delayed-onset paraparesis, seizures (37% in on cohort) and cognitive impairment (8.8%). 42% of survivors in one study had ophthalmic manifestations such as cataract and retinal hemorrhage. Depression and delirium were frequently reported.
conclusionLassa fever has significant long-term health consequences requiring multidisciplinary care. More research, particularly longitudinal and interventional studies is needed to improve post-recovery outcomes, survivor rehabilitation, inform evidence-based policies and guide resource allocation in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.